Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors
“I am proud to work alongside the highly experienced, respected and distinguished biopharma and healthcare industry leaders that comprise our Board of Directors, and we are honored to welcome Dr.
Mr. Hatfield continued, “We extend our deep appreciation to Bruce and Fran for their commitment and service to
“Zafgen’s approach to addressing complex metabolic diseases has the potential to make an important difference for patients affected by type 2 diabetes, Prader-Willi syndrome and other serious conditions,” said Dr. Everett. “I’ve spent my career on the leading edge of healthcare innovation, and I look forward to being part of the Zafgen Board of Directors as the Company advances its novel clinical development programs and works to meet its R&D, patient community and financial goals.”
Peter Barrett, Ph.D., Chairman, Partner at Atlas Venture Thomas O. Daniel, M.D., Former Chairman of Research, Celgene Corporation Wendy Everett, Sc.D., Special Advisor, Network for Excellencein Health Innovation (NEHI) Jeffrey S. Hatfield, Chief Executive Officer, Zafgen Thomas E. Hughes, Ph.D., President and Chief Scientific Officer, Zafgen John LaMattina, Ph.D., Former President of Pfizer Global R&D C. Geoffrey McDonough, M.D., President and Chief Executive Officer, Generation Bio Robert J. Perez, Former Chief Executive Officer, Cubist Pharmaceuticals, Inc. Frank E. Thomas, Chief Financial Officer and Chief Business Officer, Orchard Therapeutics
Safe Harbor Statement
Various statements in this release concerning Zafgen’s future expectations, plans and prospects, including without limitation, Zafgen’s expectations regarding the use of ZGN-1258, ZGN-1061 and other second-generation MetAP2 inhibitors as treatments for metabolic diseases including Prader-Willi syndrome, type 2 diabetes, liver diseases and obesity and Zafgen’s expectations with respect to the timing and success of its nonclinical studies and clinical trials of ZGN-1258, ZGN-1061 and its other product candidates, may constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Zafgen’s ability to successfully demonstrate the efficacy and safety of ZGN-1258, ZGN-1061 and its other product candidates and to differentiate ZGN-1258, ZGN-1061 and its other product candidates from first generation MetAP2 inhibitors, such as beloranib, the nonclinical and clinical results for ZGN-1258, ZGN-1061 and its other product candidates, which may not support further development and marketing approval, actions of regulatory agencies, which may affect the initiation, timing and progress of nonclinical studies and clinical trials of its product candidates, Zafgen’s ability to obtain, maintain and protect its intellectual property, Zafgen’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, Zafgen’s ability to manage operating expenses, Zafgen’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives when needed, Zafgen’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Zafgen’s most recent Annual Report on Form 10-K filed with the
Media/Investor Relations Contacts:
Chief Financial Officer
Ten Bridge Communications
Source: Zafgen, Inc.